Warhound Raises $200M for Gene-Edited Military Dogs

Warhound has secured $200 million in funding to develop genetically engineered dogs for the United States military. The venture is a joint effort involving Ben Lamm of Colossal Biosciences and Palmer Luckey of Anduril. Lamm stated that the company has already begun editing genes from cell samples taken from its first group of donor animals.

The initial donor pool consists of high-performing military, police, and first responder dogs across the United States. These animals are primarily Belgian Malinois, with some Labradors and shepherds included. The plan involves Colossal scientists modifying the animals' genes before cloning them. The current research focuses on reducing the likelihood of breed-specific health issues, such as hip dysplasia and certain cancers.

Lamm suggested that future genetic modifications could enhance physical traits. Additional changes might increase speed, agility, or olfactory sensitivity. The company expects the first batch of these engineered dogs to be born in early 2027. The animals will be trained for standard working dog roles, including bomb detection and search-and-rescue operations.

The founders bring distinct backgrounds to the project. Luckey previously founded Oculus VR and designed the Oculus Rift headset. His defense firm, Anduril, partnered with OpenAI in 2024 to develop artificial intelligence for the Pentagon. Anduril also recently won a U.S. Army contract to build the service's next-generation battlefield intelligence system alongside Palantir. Lamm's company, Colossal Biosciences, is known for de-extinction efforts, including projects claiming to have revived the dire wolf and aimed at resurrecting the woolly mammoth.

Anduril's role in the partnership is limited to equipment design. Warhound is not planning cyborg dogs at this stage. Instead, Anduril will create tools and software intended to protect the animals during work. This includes goggles, vests, and body armor. David Spirk, who most recently worked at Palantir, serves as the startup's CEO.

The ownership structure differs from the partnership's public profile. Luckey is a partner in the business, but neither he nor Anduril holds a stake in the startup. Colossal Biosciences holds equity, and Lamm sits on the company board.